Fennec Pharmaceuticals Inc.
FENC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001211583
In the last 90 days, Fennec Pharmaceuticals Inc. insiders filed 0 open-market purchases and 6 sales; 105 institutions reported holding it in 13F filings for Q2 2026, worth $175.1M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Fennec Pharmaceuticals Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 6 filings
- 4 insiders, $1.51M in total
- Insiders trading
- 4
- Net value
- −$1.51M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Fennec Pharmaceuticals Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Brughera Marco Maria | Director | 0 | Sep 16, 2026 | 2 |
| Raykov Rosty | Other: Former Director | 124,411 | Sep 1, 2026 | 18 |
| Sayad Pierre Sargis | Chief Medical Officer | 9,519 | Aug 31, 2026 | 6 |
| Evans Terry L | Chief Commercial Officer | 21,519 | Aug 31, 2026 | 6 |
| Cioffi Christiana Marie | Chief Strategy Officer | 24,644 | Aug 31, 2026 | 7 |
| Hackman Jeffrey S. | Chief Executive Officer | 66,302 | Aug 31, 2026 | 7 |
| Andrade Robert | CHIEF FINANCIAL OFFICER | 241,306 | Aug 31, 2026 | 18 |
| Rallis Chris A | Director | 63,077 | Jun 10, 2026 | 3 |
| Islam Khalid | Director | 213,825 | Jun 10, 2026 | 1 |
| Cook Jodi A | Director | – | Jun 10, 2026 | 1 |
| Southpoint Capital Advisors LP | 10% Owner | 2,744,741Indirect | Dec 29, 2025 | 4 |
| Southpoint GP, LP | 10% Owner | 2,744,741Indirect | Dec 29, 2025 | 4 |
| Southpoint Capital Advisors LLC | 10% Owner | 2,744,741Indirect | Dec 29, 2025 | 4 |
| Southpoint GP, LLC | 10% Owner | 2,744,741Indirect | Dec 29, 2025 | 4 |
| Clark John Smith II | 10% Owner | 2,744,741Indirect | Dec 29, 2025 | 4 |
| Haigh Adrian | CHIEF OPERATING OFFICER | 44,444 | May 21, 2024 | 0 |
| Goel Shubh | Chief Commercial Officer | – | Dec 20, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 15, 2024 (view filing) | Apr 15 | Same day | Rallis Chris ADirector | SSale | −800 | $10.45 | −$8.36K | −1.8%44.4K after | 10b5-1 |
| Apr 5, 2024 (view filing) | Apr 4-5 | 1 day | Raykov RostyCHIEF EXECUTIVE OFFICER | SSale | −88.6K | $10.82 | −$958.5K | −32.1%187.5K after | 3 lots10b5-1 |
| Apr 3, 2024 (view filing) | Apr 3 | Same day | Raykov RostyCHIEF EXECUTIVE OFFICER | SSale | −40.6K | $10.78 | −$437.5K | −12.8%276.1K after | 2 lots10b5-1 |
| Apr 3, 2024 (view filing) | Apr 1 | 2 days | Andrade RobertCHIEF FINANCIAL OFFICER | PPurchase | +12.5K | $0.00 | $0 | +13.6%104.3K after | |
| Apr 3, 2024 (view filing) | Apr 1 | 2 days | Raykov RostyCHIEF EXECUTIVE OFFICER | PPurchase | +29.2K | $0.00 | $0 | +10.1%316.6K after | |
| Mar 27, 2024 (view filing) | Mar 26 | 1 day | Rallis Chris ADirector | SSale | −2.11K | $10.97 | −$23.2K | −4.9%40.9K after | 10b5-1 |
| Mar 27, 2024 (view filing) | Mar 26 | 1 day | Andrade RobertCHIEF FINANCIAL OFFICER | SSale | −14.0K | $10.90 | −$152.3K | −13.2%91.8K after | |
| Mar 25, 2024 (view filing) | Mar 25 | Same day | Andrade RobertCHIEF FINANCIAL OFFICER | SSale | −14.0K | $11.00 | −$153.7K | −11.7%105.7K after | 10b5-1 |
| Jan 5, 2024 (view filing) | Jan 4-5 | 1 day | Andrade RobertCHIEF FINANCIAL OFFICER | SSale | −30.0K | $10.53 | −$315.8K | −20.0%119.7K after | 2 lots10b5-1 |
| Dec 29, 2023 (view filing) | Dec 28 | 1 day | Raykov RostyCHIEF EXECUTIVE OFFICER | SSale | −3.66K | $11.55 | −$42.2K | −1.3%287.5K after | |
| Dec 28, 2023 (view filing) | Dec 26 | 2 days | Rallis Chris ADirector | SSale | −1.39K | $10.90 | −$15.2K | −3.0%44.8K after | 10b5-1 |
| Nov 20, 2023 (view filing) | Nov 20 | Same day | Rallis Chris ADirector | SSale | −269 | $8.25 | −$2.22K | −0.6%43.0K after | 10b5-1 |
| Nov 9, 2023 (view filing) | Nov 8 | 1 day | Raykov RostyCHIEF EXECUTIVE OFFICER | SSale | −25.0K | $7.76 | −$194.3K | −8.1%282.6K after | 2 lots |
| Aug 18, 2023 (view filing) | Aug 18 | Same day | Rallis Chris ADirector | SSale | −673 | $7.85 | −$5.28K | −1.5%43.3K after | 10b5-1 |
| Jul 24, 2023 (view filing) | Jul 24 | Same day | Rallis Chris ADirector | SSale | −6.80K | $8.17 | −$55.5K | −13.4%44.0K after | 10b5-1 |
| Jul 6, 2023 (view filing) | Jul 6 | Same day | Rallis Chris ADirector | SSale | −2.21K | $8.47 | −$18.7K | −7.1%28.8K after | 10b5-1 |
| Jun 30, 2023 (view filing) | Jun 28-30 | 2 days | Andrade RobertCHIEF FINANCIAL OFFICER | SSale | −25.0K | $8.93 | −$223.3K | −16.7%124.7K after | 3 lots10b5-1 |
| May 19, 2023 (view filing) | May 19 | Same day | Rallis Chris ADirector | SSale | −1.76K | $7.36 | −$12.9K | −5.4%31.0K after | 2 lots10b5-1 |
| Dec 30, 2022 (view filing) | Dec 28-30 | 2 days | Raykov RostyCHIEF EXECUTIVE OFFICER | SSale | −28.7K | $9.61 | −$276.2K | −11.7%217.8K after | 4 lots |
| Dec 30, 2022 (view filing) | Dec 28-30 | 2 days | Andrade RobertCHIEF FINANCIAL OFFICER | SSale | −22.0K | $9.60 | −$211.2K | −12.8%149.7K after | 3 lots |
| Nov 17, 2022 (view filing) | Nov 17 | Same day | Rallis Chris ADirector | SSale | −333 | $7.99 | −$2.66K | −1.1%30.0K after |